Fig. 3

Sitravatinib suppresses leukemic progression in FLT3-ITD engrafted models. A Left: Schematic representation of xenograft experiments using human MOLM13 cells; Right: Schematic representation of transplant experiments using mouse BaF3-FLT3-ITD cells. B The percentage of human CD45 positive cells in BM and SP of MOLM13-diseased NSG mice detected by flow cytometry on day 24 (n = 3 mice per group). C The survival curves of MOLM13-diseased NSG mice treated with vehicle, sitravatinib (20 mg/kg/day), gilteritinib (30 mg/kg/day) or quizartinib (10 mg/kg/day) (n = 7 mice per group). D The percentage of GFP positive cells in BM and SP of BaF3-FLT3-ITD-diseased BALB/c mice on day 11 (n = 3 mice per group). E The survival curves of BaF3-FLT3-ITD-diseased mice treated with vehicle (n = 11), sitravatinib (20 mg/kg/day, n = 9), gilteritinib (30 mg/kg/day, n = 10) or quizartinib (10 mg/kg/day, n = 10). Error bars indicate mean ± standard error, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001